Shockwave IVL is an endovascular option that enables superior vessel preparation and provides excellent long-term results in the upper leg, overcoming historic challenges in treatment. For instance:
However, with Shockwave IVL’s purpose-built catheters, you can safely modify calcium at ultra-low pressure, thanks to a mechanism of action (MOA) that manages concerns of treating calcium in high-risk vessels.
1 Armstrong et. al. Cardiovascular Revascularization Medicine, 2020
2 Wong et al. CCI, 2018
3 GouëfficY et al,. JACC Cardiovasc Interv, 2017
4 Desyatova, Anastasia et al., Journal of the Royal Society Interface, 2017; 14(128)
The DISRUPT PAD III Randomized Clinical Trial (RCT) and DISRUPT PAD III Observational Study (OS) showed exceptional safety profile and proven effective calcium modification.
A 72-year-old female patient presented with lifestyle-limiting claudication and rest pain at night with worse symptoms in the left leg. The patient is a former smoker, has diabetes, CTO and chronic kidney disease (CKD). Invasive angiography of the left leg showed a chronic total occlusion in the P1 and P2 segments of the popliteal with no iliac disease and three vessel runoff to the feet. The CTO was crossed and a 3.0 mm POBA was used for the initial dilation. Then a 5.0 mm Shockwave M5+ was used along the calcified segments, finishing with a drug-coated balloon (DCB). Intravascular ultrasound (IVUS) imaging of calcified segments showed no dissections and good vessel expansion.
Intravascular Lithotripsy for Peripheral Artery Calcification: Mid-term Outcomes From the Randomized DISRUPT PAD III Trial, Tepe et al, July 2022
Endovascular Intravascular Lithotripsy in the Treatment of Calcific Common Femoral Artery Disease: A Case Series With an 18-Month Follow-Up, Baig et al, October 2022